CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6900 result(s)

Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Physical Activity

Event Date: September 23, 2020
Result type: Events

Because of the prevalence and burden of chronic pain, health care providers are in search of the best multifaceted approach for treatment knowing that relying on opioids alone can be ineffective and carries substantial risks. Join CADTH for a webinar on the current evidence on physical activity for chronic, non-cancer pain. The target audience f...

Consultation on Drug Reviews: Webinar for Industry

Event Date: July 20, 2020
Result type: Events

Pharmaceutical companies and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, the Interim Plasma Protein Product Review, and the Interim Process for Cell and Gene Therapies).  To help pharmaceutical compa...

ustekinumab (Stelara/Stelara I.V)

Last Updated: July 9, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ustekinumab
Indications: Ulcerative colitis

  • Brand Name: Stelara/Stelara I.V
  • Manufacturer: Janssen Inc.
  • Project Number: SR0627-000
  • Project Status: Active
  • Submission Type: New

burosumab (Crysvita)

Last Updated: November 28, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: burosumab
Indications: Treatment of X-Linked Hypophosphatemia

  • Brand Name: Crysvita
  • Manufacturer: Kyowa Kirin Limited
  • Project Number: SR0602-000
  • Project Status: Complete
  • Submission Type: New

Healthy Aging Interventions, Programs, and Initiatives: An Environmental Scan

Last Updated: July 10, 2020
Result type: Reports
Product Line: Environmental Scans
opens in document viewer

Summary Canadians are generally living longer in good health than previous generations. However, there is still a high risk of frailty among community-dwelling older adults. With the older adult population steadily rising in Canada, it is important that effective interventions, programs, and initiatives are developed to support the healthy ag...

  • Project Number: ES0342-000

sacubitril/valsartan (Entresto)

Last Updated: July 2, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: sacubitril/valsartan
Indications: Heart failure, NYHA Class II or III

  • Brand Name: Entresto
  • Manufacturer: Novartis Pharma Inc.
  • Project Number: SR0644-000
  • Project Status: Active
  • Submission Type: Resubmission

icosapent ethyl (Vascepa)

Last Updated: July 8, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: icosapent ethyl
Indications: Ischemic events in statin-treated patients

  • Brand Name: Vascepa
  • Manufacturer: HLS Therapeutics
  • Project Number: SR0619-000
  • Project Status: Active
  • Submission Type: New